Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6408 posts found.

hospital

The Pharma Files: With Professor Hatim Abdulhussein from Health Innovation Kent Surrey Sussex

August 28, 2025 Medical Communications, Research and Development Corporate, GP, Health Innovation Kent Surrey Sussex, The Pharma Files

Pharmafile chats with Priyanka Hinton, Customer Solutions Director at Chase People about the best parts of her job and her …
Feature

How pharma marketing needs to adapt as community pharmacies take centre stage

August 28, 2025 Business Services, Medical Communications, Sales and Marketing 10 Year Health Plan, Pharmacy, m3, pharmacy

The UK government’s 10-Year Health Plan is moving pharmacists to the frontline of primary care For decades, community pharmacies were …
Feature

European Commission approves HIV prevention injection

August 28, 2025 Medical Communications, Research and Development European Commission, Gilead Science, HIV, HIV/AIDS, US Food and Drug Administration, World Health Organisation

The European Commission (EC) has granted marketing authorisation for Gilead Science’s Yeytuo (lenacapavir), the first twice-yearly injectable medicine approved in …
News

EMA grants orphan drug designation for Roca’s treatment of radiation maculopathy

August 28, 2025 Medical Communications, Research and Development European Medicines Agency (EMA), Oncology, Opthalmology, Roca Therapeutics, maculopathy

The European Medicines Agency (EMA) has granted Orphan Drug Designation to Roca Therapeutics for its lead candidate RCT002, marking the …
News
hsm_mobile_clinical_trial_istock-872676342

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis

August 22, 2025 Medical Communications, Research and Development Hepatology, Novo Nordisk, US Food and Drug Administration, clinical trial, hepatitis, obesity

The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as a treatment for adults with …
News
epilepsy-623346_960_720

Epilepsy Research Institute opens 2025-26 grant round with new awards

August 21, 2025 Medical Communications, Research and Development Neurology, epilepsy, funding programme, medical research

The Epilepsy Research Institute has opened its 2025-26 Grant Round, offering a wide range of funding opportunities designed to support …
News

Global study calls for overhaul of hepatitis B care to meet WHO targets

August 21, 2025 Medical Communications, Medical/ Scientific Writing Hepatology, World Health Organisation, hepatitis B, liver damage, medical study

A major global study has warned that current models of hepatitis B care are failing patients and could jeopardise the …
News

Five Facts about epilepsy

August 21, 2025 Medical Communications Five Facts, Neurology, epilepsy, neurological condition, seizures

1 Epilepsy occurs when the normal electrical activity in the brain changes. For many, the cause is unclear, but genes …
Feature
brain_anatomy_medical_head_skull_digital_3_d_x_ray_xray_psychedelic_3720x2631

FDA decision on Neurizon’s ALS therapy delayed until October

August 18, 2025 Medical Communications Coya Therapeutics, Neurizon, Neurology, US Food and Drug Administration, amyotrophic lateral sclerosis

Neurizon Therapeutics has announced that the US Food and Drug Administration (FDA) will delay its decision on the company’s Clinical …
News

FDA approves first new fibromyalgia therapy in over 15 years

August 18, 2025 Medical Communications, Research and Development Pain, Tonix Pharmaceutical, US Food and Drug Administration, chronic pain, clinical trial, fibromyalgia

The US Food and Drug Administration (FDA) has approved Tonix Pharmaceutical’s Tonmya (cyclobenzaprine hydrochloric acid) for the treatment of fibromyalgia …
News
Astra Zeneca Logo

NICE recommends Benralizumab for Rare Form of Vasculitis

August 15, 2025 Medical Communications, Research and Development AstraZeneca, Immunology, National Institute for Health and Care Excellence, vasculitis

The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as an add-on treatment for adult …
News

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition

August 14, 2025 Medical Communications, Research and Development European Alliance of Associations for Rheumatology, European Medicines Agency, IgG4-related disease, Rheumatology, Sanofi

The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) inhibitor, rilzabrutinib, for the treatment …
News
eye1

Eyestem secures $10m to advance cell therapy for advanced eye disease

August 13, 2025 Medical Communications, Research and Development Eyestem, Opthalmology, cell therapy, dry age-related macular degeneration, geographic atrophy

Indian cell therapy company, Eyestem Research, has raised $10m in a funding round to support development of its investigational retinal …
News
bonecells

OS Therapies advances regulatory pathway for bone cancer therapy

August 11, 2025 Medical Communications, Research and Development European Medicines Agency’, Medicines and Healthcare products Regulatory Agency, OS Therapies, Oncology, Orthopaedics, US Food and Drug Administration’, bone cancer, osteosarcoma

OS Therapies has announced significant progress in its regulatory strategy for OST-HER2, its lead immunotherapy candidate for preventing or delaying …
News
640px-eye_iris

NICE recommends treatment for rare genetic eye disorder

August 11, 2025 Medical Communications Chiesi, Leber Hereditary Optic Neuropathy, NHS England, National Institute for Health and Care Excellence, Opthalmology, Rare Diseases

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Cheisi’s idebenone (Raxone) within its …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026